Biological therapies for psoriasis: adherence and outcome analysis from a clinical perspective
Date
2016
Authors
Ross, C.
Marshman, G.
Grillo, M.
Stanford, T.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Australasian Journal of Dermatology, 2016; 57(2):137-140
Statement of Responsibility
Christopher Ross, Gillian Marshman, Marianne Grillo and Tyman Stanford
Conference Name
Abstract
We evaluated and compared patients' long-term adherence to biological therapies in a real-life clinical setting. Secondary aims included weight changes on biological therapy and reporting adverse effects. This prospective case-note review included 58 patients, undergoing 84 treatment series including etanercept (21), adalimumab (24), infliximab (14) and ustekinumab (25). Patients' adherence was greatest with ustekinumab (being 6.7-fold less likely to withdraw from treatment than etanercept, P = 0.014), while the difference in treatment adherence of adalimumab and infliximab compared to etanercept was not statistically significant. Adalimumab and infliximab were associated with an increase in weight, while ustekinumab was associated with weight loss compared with etanercept (not statistically significant). Long-term patient adherence to biologic therapy in patients with psoriasis is greatest with ustekinumab.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2015 The Australasian College of Dermatologists